Clinical Trial

Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms

Study acronym: RUBIN
Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of the project is to set up a national, prospective, longitudinal, multicenter registry platform to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with hematological malignancies in Germany.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-09-15; most recent amendment 2026-07-10.
Status change: Not Yet Recruiting → Recruiting 2023-10-26
Trial Details
NCT Number NCT06043011
Lead Sponsor iOMEDICO AG
Conditions Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Waldenström's Macroglobulinemia (WM)
Enrollment 2,950 participants
Start Date 2023-09-27
Primary Completion 2033-12 (estimated)
Study Completion 2033-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-13